Subscribe

Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ)

CNY6.37 +0.12 (+1.92%)
CN SHZ Healthcare Biotechnology
Address Room 101, Yirui Biological Building 518101
Shenzhen, CN
CEO Zhaoli Xiao
Website bioeasy.com
IPO 2021-02-09
ISIN CNE100004C78

Explore sections of this company profile

Description

Founded in 2007 and headquartered in Shenzhen, China, Shenzhen Bioeasy Biotechnology Co., Ltd. specializes in the development and commercialization of rapid testing instruments and reagents throughout the Chinese market. The company's comprehensive diagnostic equipment addresses a wide array of applications, spanning food and agricultural analysis, dairy, meat, and aquatic product testing, honey quality control, drug detection, public safety measures, and clinical diagnostics.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY6.37 +0.12 (+1.92%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
0.40
Float Shares
382.40M
Free Float %
94.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.76% -7.97% -15.08% -33.53% -34.38% -28.80% -28.50% -50.59% -76.54% -81.41% -81.41%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
6.37
Quality scores
Altman Z-Score
3.80
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +17.4% ★ Q1'26: +16.8% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -25.0% Q1'26: -204.8% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +4.0% Q1'26: -80.6% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    +15.1% ★ Q1'26: -11.1% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    +5.6% ★ Q1'26: -2.7% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +7.1% Q1'26: +0.6% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    6.23× ★ Q1'26: -17.55× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.48) × ERP
WACC = 88% × Ke + 12% × Kd (6.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 6.37
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-28 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-27 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-26 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-25 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-22 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-21 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-20 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-19 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-18 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-15 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-14 C+ 2/5 1/5 3/5 4/5 2/5 1/5 2/5
2026-05-13 C+ 2/5 1/5 3/5 3/5 2/5 1/5 2/5
2026-05-12 C+ 2/5 1/5 3/5 3/5 2/5 1/5 2/5
2026-05-11 C+ 2/5 1/5 3/5 3/5 2/5 1/5 2/5
2026-05-08 C 2/5 1/5 2/5 3/5 1/5 1/5 2/5
2026-05-07 C 2/5 1/5 2/5 3/5 1/5 1/5 2/5
2026-05-06 C 2/5 1/5 2/5 3/5 1/5 1/5 2/5
2026-04-30 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-29 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-28 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-27 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-24 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-23 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-22 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-21 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-20 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-17 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5
2026-04-16 C 2/5 1/5 2/5 4/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-528.5K
OE per share TTM
-0.01
Owner's Yield
-0.02%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
83.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
82.9K
Shares Outstanding
405.08M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Guang Sheng Wang Financial Director — male
Jin Long Zhang Deputy General Manager — male
Rui Jie Zhang Accounting Supervisor — —
Wentian Li Deputy GM, Secretary & Non-Independent Director — female
Zhaoli Xiao Chairman & GM — male
Zhiying Chen Deputy GM & Non-Independent Director — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology